Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
Dementia01:30

Dementia

687
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
687
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ChatGPT-assisted pain history-taking system for musculoskeletal rehabilitation: Development and preliminary psychometric validation.

Musculoskeletal science & practice·2026
Same author

Conceptualizing Functioning Levels of Theory of Mind Ability and Performance in Preschool to School-Aged Autistic and Neurotypical Children.

Autism research : official journal of the International Society for Autism Research·2026
Same author

Age-related neural inefficiency: fNIRS evidence of prefrontal hyperactivation during emotional response inhibition.

GeroScience·2026
Same author

Enhancing empathy and attitudes toward dementia among formal caregivers through virtual reality: a randomized controlled trial.

Innovation in aging·2026
Same author

Development and evaluation of essential information elements for palliative care consultation: A documentation quality analysis.

Journal of the Formosan Medical Association = Taiwan yi zhi·2026
Same author

Development and performance validation of an automated GPT-based evaluation tool for the PEDro scale.

Archives of physical medicine and rehabilitation·2026

Related Experiment Video

Updated: May 4, 2026

Lexical Decision Task for Studying Written Word Recognition in Adults with and without Dementia or Mild Cognitive Impairment
06:48

Lexical Decision Task for Studying Written Word Recognition in Adults with and without Dementia or Mild Cognitive Impairment

Published on: June 25, 2019

8.7K

Developing machine learning-enhanced WHODAS 2.0 short forms for persons with dementia.

Gong-Hong Lin1, Yi-Ching Wang2, Shih-Chieh Lee3

  • 1International PhD Program in Gerontology and Long-Term Care, College of Nursing, Taipei Medical University, Taipei, Taiwan.

Journal of the Formosan Medical Association = Taiwan Yi Zhi
|May 2, 2026
PubMed
Summary
This summary is machine-generated.

Machine learning developed short forms of the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) significantly reduce assessment burden in dementia care. These new tools offer reliable and valid alternatives for disability assessment, aiding care planning.

Keywords:
DementiaDisability evaluationMachine learningPsychometric validation

More Related Videos

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

2.0K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.0K

Related Experiment Videos

Last Updated: May 4, 2026

Lexical Decision Task for Studying Written Word Recognition in Adults with and without Dementia or Mild Cognitive Impairment
06:48

Lexical Decision Task for Studying Written Word Recognition in Adults with and without Dementia or Mild Cognitive Impairment

Published on: June 25, 2019

8.7K
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

2.0K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.0K

Area of Science:

  • Gerontology
  • Neuroscience
  • Health Informatics

Background:

  • Disability assessment in dementia is crucial for care planning.
  • The full World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) is time-intensive, limiting clinical utility.
  • Developing efficient assessment tools is essential for dementia care.

Purpose of the Study:

  • To develop and validate machine learning (ML)-based short forms of the WHODAS 2.0 for dementia disability assessment.
  • To evaluate the reliability, concurrent validity, and responsiveness of these ML-based short forms.
  • To compare the performance of ML short forms against the full WHODAS 2.0 and a standard short form.

Main Methods:

  • Utilized a large dataset of 51,245 persons with dementia for training and validation.
  • Developed two ML short forms (ML-WHODAS-16 and ML-WHODAS-10) using Extreme Gradient Boosting and bootstrap-based item selection.
  • Compared ML short forms with the full WHODAS-32 and a 12-item short form (Standard-12), assessing anchor-based longitudinal validity.

Main Results:

  • Both ML short forms demonstrated high internal consistency (α=0.96 and 0.93) and excellent concurrent validity (r=0.98) with the full WHODAS-32.
  • ML short forms showed lower error and negligible bias compared to the Standard-12, meeting equivalence criteria.
  • Responsiveness was comparable to the Disability Severity Grade, with identified minimal clinically important differences.

Conclusions:

  • ML-WHODAS-16 and ML-WHODAS-10 offer practical, low-burden alternatives for dementia disability assessment.
  • These short forms closely reflect full WHODAS-32 scores, suitable for group-level and longitudinal monitoring.
  • Further external validation and testing are needed for individual-level interchangeability.